Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review
Restricted accessReview articleFirst published online September, 2021
Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: A systematic review
The drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a drug-induced hypersensitivity reaction.
Aims:
Aim was to review reports of clozapine-related reactions fulfilling the registry of severe cutaneous adverse reaction (RegiSCAR) criteria for DRESS syndrome reported as such or otherwise, to provide a descriptive overview of demographic patterns, clinical manifestations, and DRESS course and investigate associations between demographic, DRESS parameters, and clinical outcomes.
Methods:
This review was conducted following preferred reporting items for systematic reviews and meta-analyses guidelines and registered with PROSPERO (registration number CRD42020156385). We searched PubMed/Embase/PsychInfo/Cochrane for reports of clozapine-related reactions meeting RegiSCAR criteria. Associations between RegiSCAR scores and time-to-recovery with demographic/clinical variables were assessed. Demographic/clinical characteristics of patients with versus without reported DRESS were compared using non-parametrical tests.
Results:
We identified 26 reports of 27 patients meeting RegiSCAR criteria. Males (n = 19, 70.4%) and patients with schizophrenia (n = 18, 66.7%) were mainly affected. Twelve patients (44.4%) received clozapine-monotherapy. DRESS symptoms manifested within a month after clozapine initiation (n = 24, 88.9%). Lungs and liver were the most common organs involved (n = 12, 44.4%; n = 11, 40.7%), with a mean time to recovery of 33.75 days. Clozapine rechallenge led to DRESS recurrence in four patients. Death rate was 7.4%. No associations were detected between RegiSCAR criteria or days to recovery with any demographic/clinical variables. No differences between patients with versus without reported DRESS were detected.
Conclusions:
Clozapine-related DRESS may be rare, but also underreported. Clinicians need to be aware of it even in patients under clozapine-monotherapy or without skin rash.
AdwanMH (2017) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome and the rheumatologist. Current Rheumatology Reports19(1): 3.
2.
AndersonAGGaffyCBWeseliJR, et al. (2019) Inhibition of Epstein-Barr virus lytic reactivation by the atypical antipsychotic drug clozapine. Viruses11(5): 450.
3.
Anıl YağcıoğluAEErtuğrulAKarakaşlıAA, et al. (2019) A comparative study of detection of myocarditis induced by clozapine: With and without cardiac monitoring. Psychiatry Research279: 90–97.
4.
AuAFLuthraVSternR (2004) Clozapine-induced acute interstitial nephritis. The American Journal of Psychiatry161(8): 1501.
5.
BeheraSKDasSXavierAS, et al. (2018) DRESS syndrome: A detailed insight. Hospital Practice46(3): 152–162.
6.
BellissimaBLTingleMDCicovićA, et al. (2018) A systematic review of clozapine-induced myocarditis. International Journal of Cardiology259: 122–129.
7.
BelloniEDe CobelliFEspositoA, et al. (2007) Myocarditis associated with clozapine studied by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance9(3): 591–593.
8.
Ben-AriKGoldbergIShiraziI, et al. (2008) An unusual case of DRESS syndrome. Journal of Dermatological Case Reports2(3): 39–42.
9.
BenningTB (1998) Clozapine-induced extrinsic allergic alveolitis. British Journal of Psychiatry173: 440–441.
10.
BernardoMComaAIbáñezC, et al. (2012) Antipsychotic polypharmacy in a regional health service: A population-based study. BMC Psychiatry12: 42.
11.
BuggeENissenTWynnR (2016) Probable clozapine-induced parenchymal lung disease and perimyocarditis: A case report. BMC Psychiatry16(1): 438.
12.
CacoubPMusettePDescampsV, et al. (2011) The DRESS syndrome: A literature review. The American Journal of Medicine124(7): 588–597.
13.
CamousXCalboSPicardD, et al. (2012) Drug reaction with eosinophilia and systemic symptoms: An update on pathogenesis. Current Opinion in Immunology24(6): 730–735.
14.
CastellsM (2017) Diagnosis and management of anaphylaxis in precision medicine. The Journal of Allergy and Clinical Immunology140(2): 321–333.
15.
ChanSYCheungCYChanPT, et al. (2015) Clozapine-induced acute interstitial nephritis. Hong Kong Medical Journal21(4): 372–374.
16.
CharltonBG (2005) Self-management of psychiatric symptoms using over-the-counter (OTC) psychopharmacology: The S-DTM therapeutic model - Self-diagnosis, self-treatment, self-monitoring. Medical Hypotheses65(5): 823–828.
17.
ChatterjeeASaffermanAZ (1997) Cellulitis, eosinophilia, and unilateral pleural effusion associated with clozapine treatment. Journal of Clinical Psychopharmacology17(3): 232–233.
18.
ChopraNde LeonJ (2016) Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy. International Journal of Psychiatry in Medicine51(1): 104–115.
19.
CohenRLysenkoAMalletT, et al. (2015) A case of clozapine-induced myocarditis in a young patient with bipolar disorder. Case Reports in Cardiology2015: 283156.
20.
CorneliHM (2017) DRESS syndrome: Drug reaction with eosinophilia and systemic symptoms. Pediatric Emergency Care33(7): 499–502.
21.
DainJGNicolettiJBallardF (1997) Biotransformation of clozapine in humans. Drug Metabolism and Disposition25(5): 603–609.
22.
de FilippisRSoldevila-MatíasPDe FazioP, et al. (2020) Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: A systematic review. Expert Review of Clinical Pharmacology13(8): 875–883.
Dimitri ValenteGDusiNLasalviaA (2018) An idiosyncratic, acute, systemic, and life-threatening adverse reaction in a young patient treated with clozapine: A case report. Journal of Clinical Psychopharmacology38(4): 387–389.
25.
DrussBGMazureCM (1993) Transient fever and hematologic abnormalities during clozapine use. Journal of Clinical Psychopharmacology13(2): 155–156.
26.
DyerC (2018) Coroners warn health secretary of clozapine deaths. BMJ363: k5421.
27.
FehilySRForlanoRFitzgeraldPB (2016) C-reactive protein: An early critical sign of clozapine-related myocarditis. Australasian Psychiatry24(2): 181–184.
28.
FineschiVNeriMRiezzoI, et al. (2004) Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment. International Journal of Legal Medicine118(5): 307–309.
29.
Fiszenson-AlbalaFAuzerieVMaheE, et al. (2003) A 6-month prospective survey of cutaneous drug reactions in a hospital setting. The British Journal of Dermatology149(5): 1018–1022.
30.
FongSYYAu YeungKLToshJMY, et al. (2005) Clozapine-induced toxic hepatitis with skin rash. Journal of Psychopharmacology19(1): 107.
31.
FortunaGSalas-AlanisJCGuidettiE, et al. (2012) A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: A real and separate nosological entity?Journal of the American Academy of Dermatology66(6): 988–994.
32.
FrankenburgFRKandoJ (1992) Eosinophilia, clozapine, and pancreatitis. The Lancet340(8813): 251.
33.
GarlippPRosenthalOHaltenhofH, et al. (2002) The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: Implications for clinical care, recognition and management. Journal of Psychopharmacology16(4): 399–400.
34.
GhannamMMansourSNabulsiA, et al. (2017) Anticonvulsant hypersensitivity syndrome after phenytoin administration in an adolescent patient: A case report and review of literature. Clinical and Molecular Allergy15: 14.
35.
GuinartDMisawaFRubioJM, et al. (2020) Outcomes of neuroleptic malignant syndrome with depot versus oral antipsychotics. The Journal of Clinical Psychiatry82(1): 20r13272.
36.
HagiwaraHFukushimaAIwanoH, et al. (2018) Refractory cardiac myocarditis associated with drug rash with eosinophilia and systemic symptoms syndrome due to anti-bipolar disorder drugs: A case report. European Heart Journal - Case reports2(4): yty100.
37.
HassineHOualiUOuertaniA, et al. (2017) Clozapine-induced DRESS syndrome with multiple and rare organ involvement. Asian Journal of Psychiatry28: 146–147.
38.
HattonJLBhatPKGandhiS (2015) Clozapine-induced myocarditis: Recognizing a potentially fatal adverse reaction. Texas Heart Institute Journal42(2): 155–157.
39.
HoY-CLinH-L (2017) Continuation with clozapine after eosinophilia: A case report. Annals of General Psychiatry16: 46.
40.
HübnerSTBertoliRRätz BravoAE, et al. (2018) C-reactive protein and procalcitonin in case reports of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome. International Archives of Allergy and Immunology176(1): 44–54.
41.
HuttonBSalantiGCaldwellDM, et al. (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Annals of Internal Medicine162(11): 777–784.
42.
KaneJMCorrellCU (2016) The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry73(3): 187.
43.
KangSHLeeJ-I (2013) Eosinophilia, pleural effusion, hepatitis, and jaundice occurring early in clozapine treatment. Clinical Psychopharmacology and Neuroscience11(2): 103–105.
44.
KardaunSHSekulaPValeyrie-AllanoreL, et al. (2013) Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. The British Journal of Dermatology169(5): 1071–1080.
45.
KardaunSHSidoroffAValeyrie-AllanoreL, et al. (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist?The British Journal of Dermatology156(3): 609–11.
46.
KardaunSHMockenhauptMRoujeauJ-C (2014) Comments on: DRESS syndrome. Journal of the American Academy of Dermatology71(5): 1000–1000.e2.
47.
KarmacharyaRMinoMPirlWF (2005) Clozapine-induced eosinophilic colitis. The American Journal of Psychiatry162(7): 1386–1387.
48.
LebrunSDoughertyRMazurkiewiczR (2018) Clozapine induced myocarditis: A potentially silent and fatal threat. Journal of the American College of Cardiology71(11): A2438.
49.
LimASivakumaranPIsraelM (2003) Clozapine-associated polyserositis. The New Zealand Medical Journal116(1184): U651.
50.
LozanoRMarinRSantacruzM-J, et al. (2015) Selective immunoglobulin M deficiency among clozapine-treated patients: A nested case-control study. The Primary Care Companion for CNS Disorders17(4): 10.4088/PCC.15m01782.
51.
LuoDMcCollPWalmsleyR (2007) Acute onset of ascites with clozapine-induced hepatitis. Internal Medicine Journal37(3): 204–205.
52.
ManfrediRSabbataniS (2007) Clozapine-related agranulocytosis associated with fever of unknown origin, protective hospitalisation, and multiple adverse events related to the administration of empiric antimicrobial treatment. Pharmacoepidemiology and Drug Safety16(12): 1285–1289.
53.
ManuPLapitskayaYShaikhA, et al. (2018) Clozapine rechallenge after major adverse effects: Clinical guidelines based on 259 cases. American Journal of Therapeutics25(2): e218–e223.
54.
MasopustJUrbanAValisM, et al. (2009) Repeated occurrence of clozapine-induced myocarditis in a patient with schizoaffective disorder and comorbid Parkinson’s disease. Neuro Endocrinology Letters30(1): 19–21.
55.
MerrillDBAhmariSEBradfordJ-ME, et al. (2006) Myocarditis during clozapine treatment. The American Journal of Psychiatry163(2): 204–208.
56.
MoazezCRudhaYNarangN, et al. (2018) A rare presentation of clozapine-induced DRESS syndrome. Case Reports in Medicine2018: 1346351.
57.
MohanTChuaJKartikaJ, et al. (2013) Clozapine-induced nephritis and monitoring implications. The Australian and New Zealand Journal of Psychiatry47(6): 586–587.
58.
MorikawaYKuribayashiKSaitoK (1990) B-cell-mediated regulation of delayed-type hypersensitivity. Cellular Immunology131(2): 338–351.
59.
MukherjeeSEraNMukherjeeM, et al. (2019) Leukocytoclastic vasculitis secondary to clozapine. Indian Journal of Psychiatry61(1): 94–96.
60.
NaranjoCABustoUSellersEM, et al. (1981) A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics30(2): 239–245.
61.
NguyenTFritzPMarboeC, et al. (2017) Cardiogenic shock causing death after initiation of clozapine during a gastroenteritis outbreak. In: American Thoracic Society 2017 international conference, Washington, DC, 19–24 May.
62.
NielsenJYoungCIfteniP, et al. (2016) Worldwide differences in regulations of clozapine use. CNS Drugs30(2): 149–161.
63.
NuttDJBlierP (2016) Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology. Journal of Psychopharmacology30(5): 413–415.
64.
PalominaoAKukoyiOXiongGL (2010) Leukocytosis after lithium and clozapine combination therapy. Annals of Clinical Psychiatry22(3): 205–206.
65.
ParekhRFattahZSahotaD, et al. (2014) Clozapine induced tubulointerstitial nephritis in a patient with paranoid schizophrenia. BMJ Case Reports2014: bcr2013203502.
66.
PatelJJLisiPALatharaZ, et al. (2012) Clozapine-induced peripheral and pleural fluid eosinophilia. The Annals of pharmacotherapy46(2): e4.
67.
PathakSCherrySSamadS, et al. (2019) Successful clozapine rechallenge in a patient with suspected drug induced lupus. BMJ Case Reports12(4): e228574.
68.
PelizzaLMelegariM (2007) Clozapine-induced microscopic colitis: A case report and review of the literature. Journal of clinical psychopharmacology27(6): 571–574.
69.
Pereira de SilvaNPiquioniPKochenS, et al. (2011) Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs. European Journal of Clinical Pharmacology67(5): 463–470.
70.
PeterJGLehloenyaRDlaminiS, et al. (2017) Severe delayed cutaneous and systemic reactions to drugs: A global perspective on the science and art of current practice. The Journal of Allergy and Clinical Immunology: In practice5(3): 547–563.
71.
PeyrièreHDereureOBretonH, et al. (2006) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist?The British Journal of Dermatology155(2): 422–428.
72.
PonsfordMCastleDTahirT, et al. (2019) Clozapine is associated with secondary antibody deficiency. The British Journal of Psychiatry214(2): 83–89.
73.
PonsfordMJStevenRBramhallK, et al. (2020) Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID). Journal of Clinical Pathology73(9): 587–592.
74.
RamiAFBarkanDMevorachD, et al. (2006) Clozapine-induced systemic lupus erythematosus. The Annals of Pharmacotherapy40(5): 983–985.
75.
RheeDWDiuguid-GerberJKondrackeA (2019) Five cases of clozapine-associated cardiotoxicity and implications for monitoring. Psychosomatics60(5): 524–527.
76.
RittmannsbergerH (1996) Asterixis induced by psychotropic drug treatment. Clinical Neuropharmacology19(4): 349–355.
77.
RøgeRMøllerBKAndersenCR, et al. (2012) Immunomodulatory effects of clozapine and their clinical implications: What have we learned so far?Schizophrenia Research140(1–3): 204–213.
78.
RonaldsonKJTaylorAJFitzgeraldPB, et al. (2010) Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. The Journal of Clinical Psychiatry71(8): 976–981.
79.
SanaderBGrohmannRGrötschP, et al. (2019) Clozapine-Induced DRESS Syndrome: A Case Series From the AMSP Multicenter Drug Safety Surveillance Project. Pharmacopsychiatry52(3): 156–159. DOI: 10.1055/a-0586-8983.
80.
SaniGKotzalidisGDSimonettiA, et al. (2010) Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1F/1F genotype. Journal of Clinical Psychopharmacology30(6): 737–739.
81.
Schonfeldt-LecuonaCConnemannBJ (2002) Sweet’s syndrome and polyserositis with clozapine. The American Journal of Psychiatry159(11): 1947.
82.
ShioharaTKanoY (2016) Drug reaction with eosinophilia and systemic symptoms (DRESS): Incidence, pathogenesis and management. Expert Opinion on Drug Safety16(2): 139–147.
83.
SiddiquiBKAsimSShamimA, et al. (2008) Simultaneous allergic interstitial nephritis and cardiomyopathy in a patient on clozapine. NDT Plus1(1): 55–56.
84.
SimDWYuJEJeongJ, et al. (2019) Variation of clinical manifestations according to culprit drugs in DRESS syndrome. Pharmacoepidemiology and Drug Safety28(6): 840–848.
85.
SimonsonJLKlugerC (2018) Eosinophilic pleural effusion as a rare adverse effect of clozapine. Journal of General Internal Medicine33(Suppl. 1): S512–S513.
86.
SmallJGKlapperMHMalloyFW, et al. (2003) Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. Journal of Clinical Psychopharmacology23(3): 223–228.
87.
SongJMJungYEParkJH, et al. (2017) Neosensitization to multiple drugs following valproate-induced drug reaction with eosinophilia and systemic symptoms syndrome. Psychiatry Investigation14(4): 518–520.
88.
StanislavSWGonzalez-BlancoM (1999) Papular rash and bilateral pleural effusion associated with clozapine. Annals of Pharmacotherapy33(9): 1008–1009.
89.
SuvarnaPKayarkatteMNShenoiSD, et al. (2020) A rare case of clozapine induced symmetrical drug related intertriginous and flexural exanthem with vasculitis-like lesions. Contact Dermatitis82(5): 318–320.
90.
ThatcherGWCatesMBairB (1995) Clozapine-induced toxic hepatitis. The American Journal of Psychiatry152(2): 296–297.
91.
TrincasGLampugnaniDBerettaS, et al. (2017) Late onset clozapine-induced sierositis: The case of ms C. Rivista di Psichiatria52(3): 126–128.
92.
WolffKAllenRArturoJ, et al. (2018) Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology, 8th edn.New York, NY: McGraw Hill, pp.564–565.
93.
World Health Organization (WHO) (2021) The World Health Organization (WHO) global pharmacovigilance database (VigiBase). Available at: http://www.vigiaccess.org/ (accessed 9 April 2021).
94.
WuC-SChenT-YTsaiS-Y, et al. (2019) Estimating the risk of pneumonia in patients with schizophrenia newly receiving clozapine: A nationwide cohort study. Journal of Clinical Psychopharmacology39(4): 297–304.
95.
WuXTHongPWSuolangDJ, et al. (2017) Drug-induced hypersensitivity syndrome caused by valproic acid as a monotherapy for epilepsy: First case report in Asian population. Epilepsy & Behavior Case Reports8: 108–110.
96.
WysokińskiAKolińskaJ (2015) Rapidly developing and self-limiting eosinophilia associated with clozapine. Psychiatry and Clinical Neurosciences69(2): 122.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
